References
- Arbyn M, Benoy I, Simoens C, et al (2009). Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev, 18, 321-30. https://doi.org/10.1158/1055-9965.EPI-08-0510
- Arbyn M, Ronco G, Anttila A, et al (2012). Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 30, 88-99. https://doi.org/10.1016/j.vaccine.2012.06.095
- Bulkmans NW, Berkhof J, Rozendaal L, et al (2007). Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year followup of a randomised controlled implementation trial. Lancet, 370, 1764-72. https://doi.org/10.1016/S0140-6736(07)61450-0
- Carestiato FN, Silva KC, Dimetz T, Oliveira LH, Cavalcanti SM (2006). Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Braz J Infect Dis, 10, 331-6.
- Castle PE, de Sanjose S, Qiao YL, et al (2012). Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine, 30, 117-22. https://doi.org/10.1016/j.vaccine.2012.05.071
- Castle PE, Fetterman B, Poitras N, et al (2009). Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol, 113, 595-600. https://doi.org/10.1097/AOG.0b013e3181996ffa
- Curado MP, Edwards B, Shin HR, et al (2007). Cancer incidence in five continents, Vol. IX. Lyon: IARC Scientific Publications No.160.
- Cuzick J, Clavel C, Petry KU, et al (2006). Overview of the european and north american studies on HPV testing in primary cervical cancer screening. Int J Cancer, 119, 1095-101. https://doi.org/10.1002/ijc.21955
- Cuzick J, Szarewski A, Cubie H, et al (2003). Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, 362, 1871-6. https://doi.org/10.1016/S0140-6736(03)14955-0
- Dudding N, Crossley J (2013). Sensitivity and specificity of HPV testing: what are the facts? Cytopathology, 24, 283-8.
- Ferreccio C, Barriga MI, Lagos M, et al (2013). Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. Int J Cancer, 132, 916-23. https://doi.org/10.1002/ijc.27662
- Franceschi S, Herrero R, Clifford GM, et al (2006). Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer, 119, 2677-84. https://doi.org/10.1002/ijc.22241
- Herrero R, Hildesheim A, Bratti C, et al (2000). Populationbased study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst, 92, 464-74. https://doi.org/10.1093/jnci/92.6.464
- Ito K, Tsunematsu M, Satoh K, Kakehashi M, Nagata Y (2013). Effectiveness of cervical cancer screening based on a mathematical screening model using data from the Hiroshima Prefecture Cancer Registry. Asian Pac J Cancer Prev, 14, 4897-902. https://doi.org/10.7314/APJCP.2013.14.8.4897
- Jin XW, Lipold L, McKenzie M, Sikon A (2013). Cervical cancer screening: what's new and what's coming? Cleve Clin J Med, 80, 153-60. https://doi.org/10.3949/ccjm.80a.12092
- Junyangdikul P, Tanchotsrinon W, Chansaenroj J, et al (2013). Clinical prediction based on HPV DNA testing by hybrid capture 2 (HC2) in combination with liquid-based cytology (LBC). Asian Pac J Cancer Prev, 14, 903-7. https://doi.org/10.7314/APJCP.2013.14.2.903
- Kantathavorn N, Kietpeerakool C, Suprasert P, et al (2008). Clinical relevance of atypical squamous cells of undetermined significance by the 2001 bethesda system: experience from a cervical cancer high incidence region. Asian Pac J Cancer Prev, 9, 785-8.
- Katki HA, Schiffman M, Castle PE, et al (2013). Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis, 17, 56-63. https://doi.org/10.1097/LGT.0b013e318285437b
- Kiatiyosnusorn R, Suprasert P, Srisomboon J, et al (2010). Highgrade histologic lesions in women with low-grade squamous intraepithelial lesion cytology from a region of Thailand with a high incidence of cervical cancer. Int J Gynaecol Obstet, 110, 133-6. https://doi.org/10.1016/j.ijgo.2010.03.022
- Leinonen M, Kotaniemi-Talonen L, Anttila A, et al (2008). Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer, 123, 1344-9. https://doi.org/10.1002/ijc.23670
- Li J, Huang R, Schmidt JE, Qiao YL (2013). Epidemiological features of human papillomavirus (HPV) infection among women living in mainland China. Asian Pac J Cancer Prev, 14, 4015-23. https://doi.org/10.7314/APJCP.2013.14.7.4015
- Massad LS, Einstein MH, Huh WK, et al (2013). 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis, 17, 1-27.
- Ogilvie GS, Krajden M, van Niekerk DJ, et al (2012). Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer, 107, 1917-24. https://doi.org/10.1038/bjc.2012.489
- Othman N, Othman NH (2014). Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev, 15, 2245-9. https://doi.org/10.7314/APJCP.2014.15.5.2245
- Pan QJ, Hu SY, Zhang X, et al (2013). Pooled analysis of the performance of liquid-based cytology in populationbased cervical cancer screening studies in china. Cancer Cytopathol, 121, 473-82. https://doi.org/10.1002/cncy.21297
- Pandey S, Mishra M, Chandrawati (2012). Human papillomavirus screening in north Indian women. Asian Pac J Cancer Prev, 13, 2643-6. https://doi.org/10.7314/APJCP.2012.13.6.2643
- Rai AK, Das D, Kataki AC, et al (2014). Hybrid capture 2 assay based evaluation of high-risk HPV status in healthy women of north-east India. Asian Pac J Cancer Prev, 15, 861-5. https://doi.org/10.7314/APJCP.2014.15.2.861
- Rashid RM, Dahlui M, Mohamed M, Gertig D (2013). Adapting the Australian system: is an organized screening program feasible in Malaysia?--an overview of cervical cancer screening in both countries. Asian Pac J Cancer Prev, 14, 2141-6. https://doi.org/10.7314/APJCP.2013.14.3.2141
- Ronco G, Giorgi-Rossi P, Carozzi F, et al (2006). Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol, 7, 547-55. https://doi.org/10.1016/S1470-2045(06)70731-8
- Ronco G, Segnan N, Giorgi-Rossi P, et al (2006). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst, 98, 765-74. https://doi.org/10.1093/jnci/djj209
- Sankaranarayanan R, Nene BM, Shastri SS, et al (2009). HPV screening for cervical cancer in rural india. N Engl J Med, 360, 1385-94. https://doi.org/10.1056/NEJMoa0808516
- Sharma M, Bruni L, Diaz M, et al (2013). Using HPV prevalence to predict cervical cancer incidence. Int J Cancer, 132, 1895-900. https://doi.org/10.1002/ijc.27835
- Sukvirach S, Smith JS, Tunsakul S, et al (2003). Populationbased human papillomavirus prevalence in lampang and Songkla, thailand. J Infect Dis, 187, 1246-56. https://doi.org/10.1086/373901
- Swangvaree SS, Kongkaew P, Rugsuj P, Saruk O (2010). Prevalence of high-risk human papillomavirus infection and cytologic results in Thailand. Asian Pac J Cancer Prev, 11, 1465-8.
- Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
- Wang Y, Yu YH, Shen K, et al (2014). Cervical cancer screening and analysis of potential risk factors in 43,567 women in Zhongshan, China. Asian Pac J Cancer Prev, 15, 671-6. https://doi.org/10.7314/APJCP.2014.15.2.671
- Zhao FH, Lin MJ, Chen F, et al (2010). Performance of highrisk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from china. Lancet Oncol, 11, 1160-71. https://doi.org/10.1016/S1470-2045(10)70256-4
- Zorzi M, Del Mistro A, Farruggio A, et al (2013). Use of a highrisk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG, 120, 1260-7. https://doi.org/10.1111/1471-0528.12272
Cited by
- Performance of HPV DNA Testing with Hybrid Capture 2 in Triaging Women with Minor Cervical Cytologic Abnormalities (ASC-US/LSIL) in Northern Thailand vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10961
- Value of PAX1 Methylation Analysis by MS-HRM in the Triage of Atypical Squamous Cells of Undetermined Significance vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5843
- Application of HPV DNA Testing in Follow-up after Loop Electrosurgical Excision Procedures in Northern Thailand vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6093
- Manual Liquid Based Cytology for Pap Smear Preparation and HPV Detection by PCR in Pakistan vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.579
- High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand vol.88, pp.1, 2015, https://doi.org/10.1002/jmv.24290
- Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand vol.11, pp.6, 2016, https://doi.org/10.1371/journal.pone.0158184
- Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis vol.94, pp.6, 2018, https://doi.org/10.1136/sextrans-2017-053412